South Africa Announces AIDS Drug Venture With Swiss Lonza
February 13, 2012
Talks are underway between the Swiss drug maker Lonza and the government of South Africa to produce HIV medicines in that nation, where 5.6 million people are infected. "This joint venture, named Ketlaphela ["I will survive" in the Sotho language], will establish the first pharmaceutical plant to manufacture active pharmaceutical ingredients for antiretroviral medicines in South Africa," said Science Minister Naledi Pandor.
Agence France Presse
Proposed Intellectual Property Agreement Between E.U., India Could Affect Generic Drug Exports, Advocacy Groups Say
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)